M&T Bank Corp Sells 11,189 Shares of DexCom, Inc. (NASDAQ:DXCM)

M&T Bank Corp reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 23.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 36,843 shares of the medical device company’s stock after selling 11,189 shares during the period. M&T Bank Corp’s holdings in DexCom were worth $2,470,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. Jennison Associates LLC boosted its holdings in shares of DexCom by 1,683.2% in the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Legal & General Group Plc boosted its stake in DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after buying an additional 49,076 shares in the last quarter. Groupama Asset Managment grew its position in DexCom by 1.1% during the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after acquiring an additional 31,358 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in shares of DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of DexCom by 11.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock worth $183,298,000 after acquiring an additional 288,381 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on DXCM shares. Citigroup boosted their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler restated an “overweight” rating and set a $90.00 target price on shares of DexCom in a report on Monday, August 26th. JPMorgan Chase & Co. raised their price target on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Finally, Leerink Partners cut their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.00.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.30% of the company’s stock.

DexCom Trading Down 2.2 %

NASDAQ DXCM opened at $77.19 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $30.15 billion, a PE ratio of 46.22, a P/E/G ratio of 2.46 and a beta of 1.12. The stock’s 50 day moving average is $73.58 and its 200 day moving average is $84.99. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.